[1] Genital Herpes and Public Health: Addressing a Global Problem

[2] The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing, and pulmonary function at age 7-8 years

[3] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

[4] Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats

[5] Immunoglobulins and antibody response in children with protein-calorie malnutrition

[6] Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy

[7] A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

[8] Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses

[9] Immunological responses to monoassociated Bifidobacterium longum and their relation to prevention of bacterial invasion

[10] Validation of immunoglobulin G enzyme-linked immunosorbent assay for antibodies to pneumococcal surface adhesin A in the diagnosis of pneumococcal pneumonia among adults in Kenya

[11] Certolizumab pegol for induction of remission in Crohn's disease

[12] Human tularemia in France, 2006-2010

[13] Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

[14] Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus

[15] Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration

[16] Impaired humoral response to vaccines among HIV-exposed uninfected infants

[17] Immunodetection of pneumolysin in human urine by ELISA

[18] Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers

[19] Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

[20] Immunological effects of HIV-1 infection on the humoral response to malaria in an African population

[21] Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals

[22] Augmented antibody response to live attenuated measles vaccine in children with Plasmodium falciparum parasitaemia

[23] Reinfection of mice with respiratory syncytial virus

[24] Single point quantification of antibody by ELISA without need of a reference curve

[25] Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons

[26] Diagnosis of invasive pneumococcal disease among children in Kenya with enzyme-linked immunosorbent assay for immunoglobulin G antibodies to pneumococcal surface adhesin A

[27] Measles vaccination in severely malnourished Sudanese children

[28] Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis

[29] Epidemiology of respiratory syncytial virus infection among infants and children in Chicago

[30] Effects of maternal and infant co-infections, and of maternal immunisation, on the infant response to BCG and tetanus immunisation

[31] The acquisition of herpes simplex virus during pregnancy

[32] Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

[33] Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

[34] Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice

[35] Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections

[36] Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants

[37] Pneumococcal immune complexes in the diagnosis of lower respiratory infections in children

[38] First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial

[39] Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

[40] Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses

[41] Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60

[42] Lymphocyte subpopulations and antibody levels in immunized malnourished children

[43] Herpes simplex virus type 2 in the United States, 1976 to 1994

[44] Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples

[45] Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection

[46] Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial

[47] Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

[48] Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies

[49] An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes

[50] Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection

[51] The immune response to a meningococcal polysaccharide vaccine in an African village

[52] The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2

[53] Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi

[54] Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection

[55] The immunologic response to infection with respiratory syncytial virus in infants

[56] Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein

[57] Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

[58] Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus

[59] Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice

[60] Vedolizumab for induction and maintenance of remission in ulcerative colitis

[61] Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

[62] Loss of cellular immune reactivity during acute Plasmodium falciparum malaria

[63] Effectiveness of measles vaccine given simultaneously with DTP

[64] Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection

[65] The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection

[66] The laboratory confirmation of suspected measles cases in settings of low measles transmission: conclusions from the experience in the Americas

[67] Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine

[68] Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment

[69] Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

[70] The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants

[71] Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections

[72] Prolactin has a pathogenic role in systemic lupus erythematosus

[73] Hemophagocytosis in dengue: comprehensive report of six cases

[74] The immunological response to polyvalent meningococcal vaccine in Bauchi State, Nigeria

[75] Immune response to Bordetella pertussis is associated with season and undernutrition in Senegalese children

[76] Respiratory syncytial virus infection in anti-mu-treated mice

[77] Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication

[78] Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status

[79] Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

[80] Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh

[81] Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus

[82] Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers

[83] Comparative virulence of respiratory syncytial virus subgroups A and B

[84] Malnutrition and seroconversion following measles immunization

[85] Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

[86] Vedolizumab as induction and maintenance therapy for ulcerative colitis

[87] Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat

[88] Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination

[89] Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

[90] Local antibody production and respiratory syncytial virus infection in children with leukaemia

[91] Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals

[92] Risk factors for the sexual transmission of genital herpes

[93] Virus-specific IgE and IgG4 antibodies in serum of children infected with respiratory syncytial virus

[94] Pathogenesis of bronchiolitis--epidemiologic considerations

[95] Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection

[96] Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells

[97] Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement

[98] The role of TH1 and TH2 cells in a rodent malaria infection

[99] An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

[100] Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men

[101] Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant